Follow-up studies confirmed the radiosensitizing effect of PARP1 inhibitors on S-phase cells not only in fibroblasts carrying capillary ataxia mutation genes (173) but also in human lung, breast, glioma, and head and neck cancer cells (106, 172, 174, 175). Here, PARP1 is linked to central nervous system cancer.